Poor-quality drug has been bought even when the gold-standard has been available – and sits on hospitals shelves today
Reporting by the Bureau reveals that at least a dozen brands of asparaginase, a key childhood cancer drug, have been proven to be poor quality, with ten still on the market.
How Big Pharma and various government officials worked to water down a radical proposal aimed at giving poorer countries greater access to vaccines
We tell the stories that matter. To help defend quality reporting and spark change, please support the BureauDonate now
Subscribe to the Bureau newsletter, and hear when our next story breaks.